Company Profile

  • Categories:About Us
  • Time of issue:2019-05-24 00:00:00
  • Views:0

Founded in 2017, it has been the mission of Nanjing IASO Biotherapeutics (IASO BIO) to become a leading biopharmaceutical company focused on the discovery, development and commercialization of cell therapies in the field of oncology.

IASO BIO stands out through innovation, a world class facility, and an internationally renowned clinical research team that has treated more than 400 patients. Curing many who continually failed through multiple-lines of therapy, by means of detailed and thorough pathological analysis and follow up.

IASO BIO is dedicated to curing cancer using engineered autologous/allogenic T cell therapies designed to enhance the immune system's ability to recognize and eradicate cancer cells. Safety is dramatically enhanced via a proprietary procedure, minimizing the severity of CRS. Currently, IASO BIO is developing over 10 high-potential pharmaceutical products, targeting hematological tumors, solid tumors and virus associated tumors.